Skip to Main Content

Biogen (BIIB), it’s your turn.

I’m speaking of an acquisition, of course. The $9 billion purchase of Juno Therapeutics by Celgene announced Monday, which followed Gilead Sciences’s nearly $12 billion acquisition of Kite Pharma last year, shifts the M&A spotlight to Cambridge-based Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.